相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella
Wilson Lim et al.
MEDICAL MYCOLOGY (2022)
Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma
Wilson Lim et al.
PLOS NEGLECTED TROPICAL DISEASES (2022)
Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Wilson Lim et al.
EXPERT OPINION ON DRUG DISCOVERY (2022)
Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole
Bertrand Nyuykonge et al.
MYCOSES (2022)
Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma
Bertrand Nyuykonge et al.
MYCOSES (2022)
Development and Validation of an In Vitro Resazurin-Based Susceptibility Assay against Madurella mycetomatis
S. O. Abd Algaffar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Melanin production in coelomycetous agents of black grain eumycetoma
Wilson Lim et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2021)
In vitro susceptibility testing for black grain eumycetoma causative agents
Wendy W. J. van de Sande
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2021)
Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease
Pollyanna Alvaro Sposito et al.
EXPERIMENTAL PARASITOLOGY (2021)
Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer
Tao Lu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)
Modelling the spatial distribution of mycetoma in Sudan
Rowa Hassan et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2021)
The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma
Mickey Konings et al.
PLOS NEGLECTED TROPICAL DISEASES (2021)
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim
Wilson Lim et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018
Doudou Sow et al.
PLOS ONE (2020)
The global distribution of actinomycetoma and eumycetoma
Darcy Emery et al.
PLOS NEGLECTED TROPICAL DISEASES (2020)
Nigrograna mackinnonii, Not Trematosphaeria grisea (syn., Madurella grisea), Is the Main Agent of Black Grain Eumycetoma in Latin America
Sarah A. Ahmed et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis
Wendy Kloezen et al.
MEDICAL MYCOLOGY (2018)
Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma
Wilson Lim et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates
J. B. Buil et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Combining two antifungal agents does not enhance survival of Galleria mellonella larvae infected with Madurella mycetomatis
Kimberly Eadie et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2017)
Mycetoma: a unique neglected tropical disease
Eduard E. Zijlstra et al.
LANCET INFECTIOUS DISEASES (2016)
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Jason D. Oliver et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Predictors of Post-operative Mycetoma Recurrence Using Machine-Learning Algorithms: The Mycetoma Research Center Experience
Ali Wadal et al.
PLoS Neglected Tropical Diseases (2016)
Amphotericin B but not itraconazole is able to prevent grain formation in experimental Madurella mycetomatis mycetoma in mice
W. W. J. . van de Sande et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals
Sarah Abdalla Ahmed et al.
MEDICAL MYCOLOGY (2015)
A Madurella mycetomatis Grain Model in Galleria mellonella Larvae
Wendy Kloezen et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
The In Vitro Antifungal Activity of Sudanese Medicinal Plants against Madurella mycetomatis, the Eumycetoma Major Causative Agent
Hassabelrasoul Elfadil et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
In Vitro Interaction of Currently Used Azoles with Terbinafine against Madurella mycetomatis
Sarah Abdalla Ahmed et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997-2010
Michael G. Head et al.
BMJ OPEN (2014)
Madurella mycetomatis Is Highly Susceptible to Ravuconazole
Sarah Abdalla Ahmed et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
Management of mycetomas in France
S. Mattioni et al.
MEDECINE ET MALADIES INFECTIEUSES (2013)
A Histopathological Exploration of the Madurella mycetomatis Grain
Anahid Izzat Ibrahim et al.
PLOS ONE (2013)
Global Burden of Human Mycetoma: A Systematic Review and Meta-analysis
Wendy W. J. van de Sande
PLOS NEGLECTED TROPICAL DISEASES (2013)
Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan
Hagir A. M. Zein et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2012)
In Vitro Susceptibility of Madurella mycetomatis to Posaconazole and Terbinafine
Alex van Belkum et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Incidence and changing pattern of mycetoma in western Rajasthan
DevendraRaj Mathur et al.
Indian Journal of Pathology and Microbiology (2009)
Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole
Wendy W. J. van de Sande et al.
MICROBES AND INFECTION (2007)
In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi
M Cuenca-Estrella et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits
AH Groll et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method
WWJ van de Sande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5-[sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay
AOA Ahmed et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
A murine model of Madurella mycetomatis eumycetoma
AO Ahmed et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2003)
分享论文
